What this means
This trial is still recruiting people, so no results are available yet. It will look at whether melatonin changes Alzheimer's markers and thinking skills over nine months.
Plain-English summary written by an AI model from the registry listing.
- Status
- Recruiting
- Who can join
- Ages 56–85
- Where
- 1 site, including Iowa
The science
- Registered title
- Disease Modifying Potential of 5mg of Melatonin on Cognition and Brain Health in Aging
- Trial ID
- NCT03954899 ↗
- Phase
- Not applicable
- Study type
- interventional
- Conditions
- Mild Cognitive Impairment, Cognitive Decline, Healthy Aging
- What is tested
- melatonin, placebo
- Sponsor
- Natalie Denburg
- Ages
- 56 Years to 85 Years
- Dates
- First posted May 17, 2019 · updated Sep 28, 2026
Registry summary
The study will examine whether 5mg melatonin (over the counter, OTC) over a 9-month period improves Alzheimer's disease (AD) biomarkers and cognitive function in two groups of individuals: those with mild cognitive impairment (MCI+) and those who are not (MCI-). AD biomarkers will be measured from cerebrospinal fluid (CSF) obtained from lumbar punctures. Cognitive function will be evaluated with routine neuropsychological tests.
AS OF AUGUST 2024, THE LUMBAR PUNCTURE PROCEDURES FOR THIS CLINICAL TRIAL HAVE BEEN ELIMINATED. THAT IS, PARTICIPANTS ARE NO LONGER RECEIVING A LUMBER PUNCTURE. BUT ARE CONTINUING TO RECEIVE TWO SEPARATE BLOOD DRAWS FOR BIOMARKER TESTING.
Sites (1)
- University of Iowa Hospitals & Clinics, Iowa City, Iowa, United States